Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus

Michael J. Hall, MD, MS—Chair, Fox Chase Cancer Center

Sigurdis Haraldsdottir, MD—Chair, Stanford University

Abstract 480: A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.
First Author: Carl Christoph Schimanski, MD, PhD

Conclusions: The LICC trial failed to meet its primary endpoint of significantly improving RFS and OS with L-BLP25. MUC1 expression was not associated with outcome. Clinical trial information: NCT01462513. Clinical trial information: NCT01462513

Abstract 481: CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
First Author: Eric Xueyu Chen, MD, PhD

Conclusions: D+T significantly prolonged OS in pts with rCRC and preserved quality of life. Adverse events were more frequent with D+T. This is the first study showing that combined PD-L1 and CTLA-4 inhibition prolongs survival in pts with advanced refractory CRC not selected for dMMR. Clinical trial information: NCT02870920

Michael J. Overman, MD
The University of Texas MD Anderson Cancer Center
Discussion

Abstract 482: Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial.
First Author: Charlotte Emma Louise Klaver, MD, BA

Conclusions: Adjuvant HIPEC with oxaliplatin for patients with T4 or perforated colon cancer does not result in improved 18 months PMFS. Long-term results have to be awaited to assess the role of HIPEC in the adjuvant setting. Clinical trial information: NCT02231086

Abstract 483: Does a longer waiting period after neoadjuvant radiochemotherapy improve the oncological prognosis of rectal cancer? Three-year follow-up results of the GRECCAR-6 randomized multicenter trial.
First Author: Jeremie H. Lefevre, MD, PhD

Conclusions: Waiting 4 weeks longer after radiochemotherapy has no influence on the oncological outcomes of T3/T4 rectal cancers. Clinical trial information: NCT01648894

Elin R. Sigurdson, MD, PhD
Fox Chase Cancer Center
Discussion